Trial reportDiabetes technology & therapeutics2015
Hypoglycemic Accuracy and Improved Low Glucose Alerts of the Latest Dexcom G4 Platinum Continuous Glucose Monitoring System.
Trial report in Diabetes technology & therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- A Critical Discussion of Alert Evaluations in the Context of Continuous Glucose Monitoring System Performance.Journal of diabetes science and technology · 2024Review
- Clinical Performance Evaluation of Continuous Glucose Monitoring Systems: A Scoping Review and Recommendations for Reporting.Journal of diabetes science and technology · 2023Article
- Point-of-care testing technologies for the home in chronic kidney disease: a narrative review.Clinical kidney journal · 2021Article
- A retrospective in-depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management.Journal of inherited metabolic disease · 2021Article
- Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring (CGM) in Critically Ill Patients With COVID-19.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2021Article
- Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs.Clinical diabetes : a publication of the American Diabetes Association · 2021Article
- Hypoglycemic symptoms in the absence of diabetes: Pilot evidence of clinical hypoglycemia in young women.Journal of clinical & translational endocrinology · 2019Article
- Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring System's Predictive Low Glucose Alert.Diabetes technology & therapeutics · 2019Article
- Selecting the Appropriate Continuous Glucose Monitoring System - a Practical Approach.European endocrinology · 2018Review
- Automated closed-loop control of diabetes: the artificial pancreas.Bioelectronic medicine · 2018Review
- Future of Automated Insulin Delivery Systems.Diabetes technology & therapeutics · 2017Review
- Analysis of the Accuracy and Performance of a Continuous Glucose Monitoring Sensor Prototype: An In-Silico Study Using the UVA/PADOVA Type 1 Diabetes Simulator.Journal of diabetes science and technology · 2017Article
- Continuous Glucose Monitoring: A Perspective on Its Past, Present, and Future Applications for Diabetes Management.Clinical diabetes : a publication of the American Diabetes Association · 2017Article
- Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report.Diabetes care · 2016Review
- The Rationale for Continuous Glucose Monitoring-based Diabetes Treatment Decisions and Non-adjunctive Continuous Glucose Monitoring Use.European endocrinology · 2016Review
- Hypoglycemia Reduction and Accuracy of Continuous Glucose Monitoring.Diabetes technology & therapeutics · 2015Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAccuracy of continuous glucose monitoring (CGM) devices in hypoglycemia has been a widely reported shortcoming of this technology. We report the accuracy in hypoglycemia of a new version of the Dexcom (San Diego, CA) G4 Platinum CGM system (software 505) and present results regarding the optimum setting of CGM hypoglycemic alerts. MATERIALS AND
methodsCGM values were compared with YSI analyzer (YSI Life Sciences, Yellow Springs, OH) measurements every 15 min. We reviewed the accuracy of the CGM system in the hypoglycemic range using standard metrics. We analyzed the time required for the CGM system to detect biochemical hypoglycemia (70 mg/dL) compared with the YSI with alert settings at 70 mg/dL and 80 mg/dL. We also analyzed the time between the YSI value crossing 55 mg/dL, defined as the threshold for cognitive impairment due to hypoglycemia, and when the CGM system alerted for hypoglycemia.
resultsThe mean absolute difference for a glucose level of less than 70 mg/dL was 6 mg/dL. Ninety-six percent of CGM values were within 20 mg/dL of the YSI values between 40 and 80 mg/dL. When the CGM hypoglycemic alert was set at 80 mg/dL, the device provided an alert for biochemical hypoglycemia within 10 min in 95% of instances and at least a 10-min advance warning before the cognitive impairment threshold in 91% of instances in the study.
conclusionsUse of an 80 mg/dL threshold setting for hypoglycemic alerts on the G4 Platinum (software 505) may provide patients with timely warning of hypoglycemia before the onset of cognitive impairment, enabling them to treat themselves for hypoglycemia with fast-acting carbohydrates and prevent neuroglycopenia associated with very low glucose levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.